None (2022) ‘Cost Effectiveness Analysis of Rivaroxaban Compared to Warfarin and Aspirin for Stroke Prevention Atrial Fibrillation (SPAF) in the 
Indonesian healthcare setting’, Fakultas Farmasi UGM. oai:ais:library-item:7763